Executive Team

Dr. Arun Menawat is Chairman and CEO of Profound Medical Inc., a commercial-stage medical technology company that markets real-time MRI-guided thermal ultrasound systems for incision-free ablation of abnormal or cancerous tissue. Profound’s key product is the TULSA-PRO therapeutic system, designed for precise and customizable ablation of diseased prostate tissue.

Before joining Profound, Arun served as the Chairman and CEO of Novadaq Technologies Inc. for 13 years, guiding the company from a startup to one of the fastest growing, NASDAQ listed medical technology companies in North America, with a market cap of mostly over one billion USD during the final three years of his leadership. Earlier, Arun served as President of Cedara Software Corp., a company that developed the industry’s first medical imaging software platform. Today, Cedara’s imaging platform and its big data collection are part of IBM’s Watson Health.

He obtained a Ph.D. in Chemical Engineering from the University of Maryland, and an Executive MBA from the J.L. Kellogg School of Management, Northwestern University. In 2014, he was named the EY Ontario Entrepreneur of the Year in the health sciences category.

Mr. Richard Fabian has an accomplished history of sales, marketing, operations, general and executive management success within the global healthcare industry, specifically in the medical imaging and medical device spaces. In a career spanning more than 29 years, he most recently served as Chief Executive Officer of FUJIFILM Sonosite, Inc., an innovator and leader in point-of-care ultrasound. Before joining Sonosite in 2017, Mr. Fabian served in a variety of roles with Philips Healthcare, the primary healthcare and medical technology business segment and division of NYSE/AEX-listed Royal Philips. Starting in 2002 as a Senior Director in the Cardiovascular X-ray Business Unit, North America, he progressed to lead in several executive roles in sales, marketing, and global general management. Earlier in his career, Mr. Fabian was VP, Sales at Noetix Corporation (now Magnitude Angles) and VP, Operations at STERIS Corporation. Mr. Fabian received a Bachelor of Economics degree from the University of Michigan, where he was a two-time letterman on the varsity swim team, and a Master of Business Administration from the University of Pittsburgh Joseph M. Katz Graduate School of Business.

Mr. Tom Tamberrino is a seasoned leader with a distinguished career in sales and marketing leadership, business development, and executive management, with much of his success rooted in the U.S. healthcare industry. He brings a wealth of experience, including a history of entrepreneurial ventures and significant contributions to the medical technology sector. Prior to joining Profound Medical, Mr. Tamberrino served as Vice President of Sales and Marketing at Novadaq Technologies Inc. for several years. Under his leadership, Novadaq established itself as the market leader in near-infrared fluorescence imaging, achieving remarkable growth and driving revenues from an annual run rate of $27 million in 2012 to over $82 million in 2017. This growth culminated in Novadaq’s acquisition by Stryker Corporation for approximately $701 million, after which Mr. Tamberrino continued with Stryker until 2018 to support the integration of Novadaq’s business. Earlier in his career, Mr. Tamberrino held progressive sales management positions at LifeCell Corporation, eventually serving as Area Director. During his time at LifeCell Corporation, he led a 50-person sales team across the Northeastern U.S. and Canada, marketing regenerative tissue matrices. Mr. Tamberrino holds a Bachelor of Science degree in Marketing with a Minor in Psychology from Georgetown University and a Master of Business Administration from Emory University.

Matthew Sobczyk, CPA, CA is an accomplished finance executive with more than 18 years of experience leading financial strategy, capital markets transactions, corporate reporting and treasury management across public and private companies. Over his tenure at Profound Medical, he has led significant finance transformation initiatives, including the Company's transition from IFRS to U.S. GAAP, and the uplisting from the TSX Venture Exchange to the TSX and NASDAQ. Prior to joining Profound Medical, Mr. Sobczyk spent over a decade in public accounting, audit, and advisory roles with Ernst & Young LLP and MNP LLP. He led audit and advisory engagements for numerous Canadian and U.S. public companies across the technology, manufacturing, distribution, and wealth management sectors. Advising clients on IPOs, reverse takeovers, evolving accounting standards, and managed multidisciplinary teams supporting both domestic and international engagements. Mr. Sobczyk holds a Bachelor of Arts (Honours Business Administration) from the Richard Ivey School of Business at Western University and earned his Chartered Professional Accountant, Chartered Accountant (CPA, CA) designation in Ontario. He has remained active in the accounting profession and broader business community through mentorship, industry education, and volunteer leadership initiatives, including service with CPA Canada's CFE mentoring program.

Dr. Mathieu Burtnyk brings over 20 years of experience advancing imaging technologies and therapeutic ultrasound solutions from benchtop innovation to clinical adoption, with a specialized focus on prostate disease. He began his career in academia, earning his PhD in Medical Biophysics from the University of Toronto and Sunnybrook Health Sciences Center. He is the inventor of the patented closed-loop temperature feedback control algorithm that underpins the TULSA-PRO system in clinical use today.

Since joining Profound in 2011, Dr. Burtnyk has led the scientific design and execution across the full development lifecycle, including pre-clinical research, early feasibility, the TACT pivotal FDA trial, and the post-market CAPTAIN randomized controlled study supporting positive coverage, while also leading efforts to advance market access through the establishment of new reimbursement codes in the United States to enable clinical adoption.

At Profound, Mathieu drives strategic alignment between clinical and R&D organizations to accelerate the development of cutting-edge technologies that meet real-world user needs, leveraging award-winning AI innovations translated into the clinic to enhance procedural efficiency, physician experience, and patient outcomes.